Editorial
doi: 10.1080/15384101.2015.1086200.
Resistance to EGFR-targeted therapy by Ets-1 inactivation
Affiliations
- PMID: 26313421
- PMCID: PMC4825599
- DOI: 10.1080/15384101.2015.1086200
Item in Clipboard
Editorial
Resistance to EGFR-targeted therapy by Ets-1 inactivation
Cell Cycle.
2015.
No abstract available
Figures
Summary of the molecular mechanism of EGFR inhibition and innate drug resistance in EGFR-mutated NSCLC cells. Increases and decreases in activity/expression of signaling molecules or biological outcomes resulting from EGFR inhibition are indicated by red arrows.
Comment on
-
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3855-63. doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6. Proc Natl Acad Sci U S A. 2015. PMID: 26150526 Free PMC article.
Similar articles
-
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3855-63. doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6. Proc Natl Acad Sci U S A. 2015. PMID: 26150526 Free PMC article.
-
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2. Cell Rep. 2015. PMID: 25843712 Free PMC article.
-
EGF receptor in breast cancer chemoresistance.Adv Exp Med Biol. 2007;608:113-8. doi: 10.1007/978-0-387-74039-3_8. Adv Exp Med Biol. 2007. PMID: 17993236 Review. No abstract available.
-
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.Oncotarget. 2017 Jul 11;8(28):45898-45917. doi: 10.18632/oncotarget.17438. Oncotarget. 2017. PMID: 28507280 Free PMC article.
-
AKT inactivation causes persistent drug tolerance to EGFR inhibitors.Pharmacol Res. 2015 Dec;102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22. Pharmacol Res. 2015. PMID: 26453958 Review.
Cited by
-
ETS-targeted therapy: can it substitute for MEK inhibitors?Clin Transl Med. 2017 Dec;6(1):16. doi: 10.1186/s40169-017-0147-4. Epub 2017 May 2. Clin Transl Med. 2017. PMID: 28474232 Free PMC article. Review.
-
Drug Resistance to EGFR Inhibitors in Lung Cancer.Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25. Chemotherapy. 2016. PMID: 26910730 Free PMC article. Review.
-
LCN2 promotes focal adhesion formation and invasion by stimulating c-Src activation.J Cell Sci. 2025 Jun 1;138(11):jcs263663. doi: 10.1242/jcs.263663. Epub 2025 Jun 5. J Cell Sci. 2025. PMID: 40356520 Free PMC article.
-
Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.Cells. 2019 Jul 18;8(7):740. doi: 10.3390/cells8070740. Cells. 2019. PMID: 31323891 Free PMC article.
References
-
- Rosell R, et al.. Lancet Oncol 2012; 13:239-46; PMID:22285168; http://dx.doi.org/10.1016/S1470-2045(11)70393-X - DOI - PubMed
-
- Wilson TR, et al.. Nature 2012; 487:505-9; PMID:22763448; http://dx.doi.org/10.1038/nature11249 - DOI - PMC - PubMed
-
- Phuchareon J, et al.. Proc Natl Acad Sci U S A 2015; 112:E3855-63; PMID:26150526; http://dx.doi.org/10.1073/pnas.1510733112 - DOI - PMC - PubMed
-
- Tricker EM, et al.. Cancer Discov 2015; 5:960–971;PMID:26036643; http://cancerdiscovery.aacrjournals.org/content/5/9/960.abstract?etoc
-
- Ercan D, et al.. Cancer Discov 2012; 2:934-47; PMID:22961667; http://dx.doi.org/10.1158/2159-8290.CD-12-0103 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
